Tumor-Activated Carrier-Free Dual-Prodrug Nanoassemblies for Synergistic Chemo-Immunotherapy
Nano Letters · 2026
DOI: 10.1021/acs.nanolett.6c02599 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nano Letters, 2026. Verfasst von Luyao Wang und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, China-Japan Union Hospital of Jilin University, Changchun, Jilin130033, China. Hauptthemen laut MEDLINE: Prodrugs, Imidazoles, Nanoparticles, Paclitaxel. Die Arbeit nennt 43 Literaturangaben. Gefördert von: Jilin Province Development and Reform Commission, Ministry of Science and Technology of the People's Republic of China, Jilin University.
Abstract (Originalsprache)
Chemo-immunotherapy is limited by the poor bioavailability, nonspecific distribution, and systemic toxicity of free drugs. Here, we develop a reactive oxygen species (ROS)-responsive prodrug strategy by conjugating paclitaxel (PTX) and the TLR7/8 agonist resiquimod (R848) with a phenylboronic ester (PBE) moiety to generate two ROS-activatable prodrugs, PTX–PBE and R848–PBE. These prodrugs spontaneously coassemble into carrier-free nanoparticles (PR NPs) with ultrahigh loading efficiency and tunable drug ratios. PBE modification improves systemic stability while enabling ROS-triggered drug release in the tumor microenvironment, allowing PTX-mediated immunogenic cell death and R848-mediated innate immune activation. In colorectal cancer models, PR NPs suppress tumor growth, reduce systemic toxicity, and remodel the tumor immune microenvironment by promoting antitumor immune responses. This prodrug engineering strategy provides a high-loading, activatable, and carrier-free platform for chemo-immunotherapy with potential for cancer treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiation Oncology, China-Japan Union Hospital of Jilin University, Changchun, Jilin130033, China.
- Key Laboratory of Polymer Chemistry and Physics of Ministry of Education, School of Materials Science and Engineering, Peking University, Beijing100871, China.
- Key Laboratory and Engineering Laboratory of Lymphatic Surgery Jilin Province, China-Japan Union Hospital of Jilin University, Changchun130033, JilinChina.
ORCID-Profile: Shixian Lv, Haochen Yao
Förderung
- Jilin Province Development and Reform Commission
- Ministry of Science and Technology of the People's Republic of China
- Jilin University
- Education Department of Jilin Province
- Department of Science and Technology of Jilin Province
- Health Commission of Jilin Province
- Science and Technology Department, Henan Province
- National Natural Science Foundation of China (NSFC)
Zitieren
APA
Wang, L., Yang, Z., Su, Y., Jin, G., Lin, S., Yu, B., Zhou, H., Zhang, Q., Zhang, S., Bi, Z., Xu, J., Xiang, S., Lv, S., Yao, H., & Liu, L. (2026). Tumor-Activated Carrier-Free Dual-Prodrug Nanoassemblies for Synergistic Chemo-Immunotherapy. Nano Letters. https://doi.org/10.1021/acs.nanolett.6c02599
Vancouver
Wang L, Yang Z, Su Y, Jin G, Lin S, Yu B, et al. Tumor-Activated Carrier-Free Dual-Prodrug Nanoassemblies for Synergistic Chemo-Immunotherapy. Nano Letters. 2026. doi:10.1021/acs.nanolett.6c02599
BibTeX
@article{Wang2026,
author = {Wang, Luyao and Yang, Zhaofan and Su, Yuanzhen and Jin, Guanyu and Lin, Shanyi and Yu, Bingzheng and Zhou, Huicong and Zhang, Qi and Zhang, Shucheng and Bi, Zhuoling and Xu, Jiawen and Xiang, Sijun and Lv, Shixian and Yao, Haochen and Liu, Linlin},
title = {Tumor-Activated Carrier-Free Dual-Prodrug Nanoassemblies for Synergistic Chemo-Immunotherapy},
journal = {Nano Letters},
year = {2026},
doi = {10.1021/acs.nanolett.6c02599}
}
EUVIMED